Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Brainstorm Cell Therapeutics Inc. (BCLI) AI Forecast

Our AI analyzed Brainstorm Cell Therapeutics Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$BCLI Neutral Signal Full forecast available
Sign Up Free

Brainstorm Cell Therapeutics Inc. (BCLI) Stock Forecast 2025

Brainstorm Cell Therapeutics Inc. (BCLI) AI Stock Price Forecast & Investment Analysis

Brainstorm Cell Therapeutics Inc. Stock Price Chart and Technical Analysis

Loading chart...

Brainstorm Cell Therapeutics Inc. (BCLI) - Comprehensive Stock Analysis & Investment Research

Deep dive into Brainstorm Cell Therapeutics Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 3:42 p.m. (UTC)

Brainstorm Cell Therapeutics Inc. Investment Summary

When evaluating whether Brainstorm Cell Therapeutics Inc. (BCLI) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Brainstorm Cell Therapeutics Inc. (BCLI) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $11 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Brainstorm Cell Therapeutics Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Brainstorm Cell Therapeutics Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Brainstorm Cell Therapeutics Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Brainstorm Cell Therapeutics Inc.

Sign Up Free
Corporate Identity

Brainstorm Cell Therapeutics Inc. (Stock Symbol: BCLI) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the OTC exchange.

Leadership & Workforce

Detailed information about Brainstorm Cell Therapeutics Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Brainstorm Cell Therapeutics Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Brainstorm Cell Therapeutics Inc....

Unlock Full Company Profile

Get complete details about Brainstorm Cell Therapeutics Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Brainstorm Cell Therapeutics Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Brainstorm Cell Therapeutics Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Brainstorm Cell Therapeutics Inc....

Unlock Financial Analysis

Get complete financial metrics for Brainstorm Cell Therapeutics Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Brainstorm Cell Therapeutics Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Brainstorm Cell Therapeutics Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Brainstorm Cell Therapeutics Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 0.02 reflects potential liquidity concerns with current liabilities exceeding current assets. While some businesses operate successfully with negative working capital, this warrants understanding of the specific circumstances.

Brainstorm Cell Therapeutics Inc. (BCLI) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Brainstorm Cell Therapeutics Inc. stock analysis.

Deep dive into Brainstorm Cell Therapeutics Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Brainstorm Cell Therapeutics Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Brainstorm Cell Therapeutics Inc.:

Market Cap $11M
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Brainstorm Cell Therapeutics Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Brainstorm Cell Therapeutics Inc.: An ROE of -1524.6% indicates room for improvement in shareholder value creation.

ROE -1524.6%
ROA 22231.5%
Tax Rate -7.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Brainstorm Cell Therapeutics Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Brainstorm Cell Therapeutics Inc.: A current ratio of 0.02 suggests potential liquidity concerns.

Current Ratio 0.02x
D/E Ratio -1.07x
Financial Leverage -0.07x
Interest Coverage -0.1x
Working Capital -$12M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Brainstorm Cell Therapeutics Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Brainstorm Cell Therapeutics Inc.:

Operating Cash Flow -$40M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Brainstorm Cell Therapeutics Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Brainstorm Cell Therapeutics Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Brainstorm Cell Therapeutics Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Brainstorm Cell Therapeutics Inc.:

Income Statement
Net Income $167M
R&D Expense -$94M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 0%
Cash & Short-term Investments 0%
Total Liabilities 12%
Short-term Debt 4%
Dividend & Shareholder Information
Shares Outstanding 11M

Latest Brainstorm Cell Therapeutics Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Brainstorm Cell Therapeutics Inc. (BCLI) stock price and investment outlook.

📰 Loading...

Brainstorm Cell Therapeutics Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Brainstorm Cell Therapeutics Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $25M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $20M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $516M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $185M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Brainstorm Cell Therapeutics Inc. Stock Forecast

How accurate are Brainstorm Cell Therapeutics Inc. stock predictions?

Our AI model shows a 5% Spearman correlation coefficient for BCLI predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Brainstorm Cell Therapeutics Inc. stock price forecasts?

Our analysis considers Brainstorm Cell Therapeutics Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Brainstorm Cell Therapeutics Inc. a good investment in 2025?

Based on our AI analysis, Brainstorm Cell Therapeutics Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Brainstorm Cell Therapeutics Inc. forecasts updated?

Brainstorm Cell Therapeutics Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Brainstorm Cell Therapeutics Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...